Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | PDK1 | Q15118 | 4/20 | 0.55 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.55 |
| ▸ | PDK3 | Q15120 | 4/20 | 0.55 |
| ▸ | PDK4 | Q16654 | 4/20 | 0.55 |
| ▸ | CETP | P11597 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1030263 | 0.85 | LMNA (0.74) | KDM4ELMNAALOX12PDK1PDK2 | |
| SCHEMBL3785961 | 0.85 | CETP (0.58) | KDM4ELMNAPDK1PDK2PDK3 | |
| SCHEMBL18021884 | 0.83 | LMNA (0.58) | KDM4ELMNAALOX12PDK1PDK2 | |
| SCHEMBL11499021 | 0.82 | KMT2A (0.50) | KDM4EKMT2ARAB9AMAPTMEN1 | |
| SCHEMBL10046356 | 0.81 | KDM4E (0.57) | KDM4ELMNAALOX12PDK1PDK2 | |
| SCHEMBL7928023 | 0.81 | LMNA (0.57) | KDM4ELMNAALOX12PDK1PDK2 | |
| SCHEMBL1983314 | 0.81 | KDM4E (0.57) | KDM4ELMNAALOX12PDK1PDK2 | |
| SCHEMBL20310343 | 0.81 | ALDH1A1 (0.58) | KDM4ELMNAKMT2ARAB9AMAPT | |
| SCHEMBL15621420 | 0.80 | PDK1 (0.69) | LMNAPDK1PDK2PDK3PDK4 | |
| SCHEMBL8806924 | 0.80 | CA12 (0.59) | KDM4ELMNAALOX12PDK1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2162431-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2017-06-07 | — | — | EP | disclosed |
| CN-102731381-B | The polysubstituted aryl of 6-()-4-aminopyridine formic acid esters and the purposes as herbicide thereof | 美国陶氏益农公司 | 2016-08-17 | — | — | CN | disclosed |
| US-20150080569-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-8809266-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20130274439-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-17 | — | — | US | disclosed |
| US-8420597-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20130053577-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-8283442-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-20120190866-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-8178491-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178491-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090257978-A1 | Antiviral coumpounds | GILEAD SCIENCES, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090257978-A1 | Antiviral coumpounds | GILEAD SCIENCES, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| WO-2009005676-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274439-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | KDM4E 2496/4885LMNA 1353/4885ALOX12 3113/4885 |
| US-20090257978-A1 | Antiviral coumpounds | MAVS, ZC3HAV1, EIF2AK2 | KDM4E 2399/4885LMNA 1597/4885ALOX12 2613/4885 |
| US-20130053577-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | KDM4E 2496/4885LMNA 1353/4885ALOX12 3113/4885 |
| US-20120190866-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | KDM4E 2496/4885LMNA 1353/4885ALOX12 3113/4885 |
| US-20150080569-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | KDM4E 2496/4885LMNA 1353/4885ALOX12 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.